Sees FY24 revenue $320M-$325M, consensus $329.05M. The company said, “The Company now expects its fiscal year 2024 net sales to be in the range of $320 to $325 million, accounting for the softer Thrombectomy sales during the fiscal second quarter, which it now expects will continue throughout the back half of the year, as well as certain SKU rationalization and other impacts associated with the manufacturing restructuring. The Company expects gross margin to be approximately 49% to 51% and adjusted loss per share in the range of $0.35 to $0.42.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ANGI:
- Angi Inc. price target raised to $3.10 from $2.50 at Citi
- U.S. Homeowners Double Down on Home Improvement Spending in 2023
- IAC price target lowered to $68 from $72 at KeyBanc
- Uber plans test of TaskRabbit-like service in select markets, Bloomberg reports
- IAC price target lowered to $62 from $75 at Barclays
